Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 10/20 | 0.64 |
| ▸ | PDE5A | O76074 | 5/20 | 0.57 |
| ▸ | PDE4A | P27815 | 5/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7025779 | 0.96 | ADORA1 (0.65) | ADORA1PDE5APDE4APDE4BPDE4C | |
| SCHEMBL7025747 | 0.95 | ADORA1 (0.64) | ADORA1PDE5APDE4APDE4BPDE4C | |
| SCHEMBL7026752 | 0.84 | PDE4A (0.60) | ADORA1PDE5APDE4APDE4BPDE4C | |
| SCHEMBL7268220 | 0.81 | PDE4A (0.87) | ADORA1PDE5APDE4APDE4BPDE4C | |
| SCHEMBL7021179 | 0.81 | PDE5A (0.61) | ADORA1PDE5APDE4APDE4BPDE4C | |
| SCHEMBL7270168 | 0.79 | PDE4A (0.89) | ADORA1PDE5APDE4APDE4BPDE4C | |
| SCHEMBL7624397 | 0.79 | ADORA1 (0.49) | ADORA1PDE5APDE4APDE4BPDE4C | |
| SCHEMBL9122257 | 0.78 | ADORA1 (1.00) | ADORA1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL7269993 | 0.78 | PDE4A (0.57) | ADORA1PDE5APDE4APDE4BPDE4C | |
| SCHEMBL7028598 | 0.77 | ADORA1 (0.88) | ADORA1MEN1KMT2AADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1120417-A2 | Xanthine derivatives for the treatment of cerebrovascular disorders | SMITHKLINE BEECHAM PHARMA GmbH (DE) | 2001-08-01 | — | — | EP | claimed |
| US-5734051-A | TREATMENT OF CEREBROVASCULAR DISORDERS AND-OR DISORDERS ASSOCIATED WITH CEREBRAL SENILITY | BEECHAM GROUP (GB) | 1998-03-31 | — | — | US | claimed |
| CN-1031641-C | Process for preparing 8-substituted xanthine | BEECHAM WUELFING GMBH & CO KG (DE) | 1996-04-24 | — | — | CN | claimed |
| CN-1047502-A | The preparation method of 8-substituted xanthine | BEECHAM WUELFING GMBH & CO KG (DE) | 1990-12-05 | — | — | CN | claimed |
| EP-0389282-A2 | Xanthinederivatives, process for their preparation and their pharmaceutical use | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1990-09-26 | — | — | EP | claimed |
| US-6531600-B1 | 8-substituted xanthines have a protective effect against the consequences of cerebral metabolic inhibition; cerebral vascular and neuronal degenerative disorders; 6-aminouracil intermediate is claimed | BEECHAM GROUP P.L.C. (GB) | 2003-03-11 | — | — | US | disclosed |
| EP-1120417-A2 | Xanthine derivatives for the treatment of cerebrovascular disorders | SMITHKLINE BEECHAM PHARMA GmbH (DE) | 2001-08-01 | — | — | EP | disclosed |
| US-6180791-B1 | REDUCING NITRO GROUPS TO FORM AMINO GROUPS | BEECHAM GROUP P.L.C. (GB) | 2001-01-30 | — | — | US | disclosed |
| US-5981535-A | FOR TREATMENT OF ALLERGIC DISORDERS ASSOCIATED WITH ATOPY, BRONCHODILATION TO TREAT DISORDERS OF THE RESPIRATORY TRACT IN A MAMMAL | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-11-09 | — | — | US | disclosed |
| US-5734051-A | TREATMENT OF CEREBROVASCULAR DISORDERS AND-OR DISORDERS ASSOCIATED WITH CEREBRAL SENILITY | BEECHAM GROUP (GB) | 1998-03-31 | — | — | US | disclosed |
| CN-1047502-A | The preparation method of 8-substituted xanthine | BEECHAM WUELFING GMBH & CO KG (DE) | 1990-12-05 | — | — | CN | disclosed |
| EP-0389282-A2 | Xanthinederivatives, process for their preparation and their pharmaceutical use | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1990-09-26 | — | — | EP | disclosed |